Physician profile
Albert Naveed
NPI 1578710232
$9,195.12
in general payments reported to CMS, 2019-2025
27 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $204 · 2021: $265 · 2022: $31.89 · 2023: $7,514 · 2024: $145 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,200 · Travel and Lodging: $1,068 · Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,199.98 |
| Travel and Lodging | $1,067.93 |
| Food and Beverage | $517.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,240.68 | 2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $408.02 | 2019-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $303.73 | 2019-2023 | Fasenra |
| Insmed, INC. | $132.28 | 2019-2024 | Arikayce |
| Mallinckrodt Hospital Products INC. | $120.78 | 2023 | Acthar |
| Ethicon INC. | $108.24 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Mylan Specialty L.P. | $94.59 | 2019-2023 | Yupelri |
| Pulmonx Corporation | $91.15 | 2021 | |
| Philips North America LLC | $80.25 | 2019-2023 | |
| Genzyme Corporation | $70.18 | 2019 | |
| Merck Sharp & Dohme LLC | $63.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.57 | 2019-2024 | Ofev |
| Avadel Cns Pharmaceuticals, LLC | $54.48 | 2024-2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $48.45 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $28.81 | 2024 | Sunosi |
| Electromed, INC. | $25.42 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.47 | 2019 | |
| Karl Storz Endoscopy-America | $21.75 | 2019 | |
| Inogen, INC. | $19.70 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Grifols USA, LLC | $16.72 | 2020 | |
| United Therapeutics Corporation | $16.26 | 2019 | |
| Olympus America INC. | $16.04 | 2023 | Evis Exera II Ultrasonic Bronchofibervideoscope, Oes Bronchofiberscope |
| Harmony Biosciences LLC | $15.50 | 2024 | |
| Nabriva Therapeutics, Plc | $13.44 | 2020 | |
| Pfizer INC. | $12.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Naveed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.